Rosa-Rosa Juan M, Leskelä Susanna, Cristóbal-Lana Eva, Santón Almudena, López-García Ma Ángeles, Muñoz Gloria, Pérez-Mies Belen, Biscuola Michele, Prat Jaime, Esther Oliva, Soslow Robert A, Matias-Guiu Xavier, Palacios Jose
Servicio de Anatomía Patológica, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.
Department of Pathology, Hospital Universitario Virgen del Rocío and Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
Mod Pathol. 2016 Nov;29(11):1390-1398. doi: 10.1038/modpathol.2016.132. Epub 2016 Aug 5.
Undifferentiated and dedifferentiated endometrial carcinomas are rare and highly aggressive subtypes of uterine cancer, not well characterized at a molecular level. To investigate whether dedifferentiated carcinomas carry molecular genetic alterations similar to those of pure undifferentiated carcinomas, and to gain insight into the pathogenesis of these tumors, we selected a cohort of 18 undifferentiated endometrial carcinomas, 8 of them with a well-differentiated endometrioid carcinoma component (dedifferentiated endometrioid carcinomas), and studied them by immunohistochemistry and massive parallel and Sanger sequencing. Whole-exome sequencing of the endometrioid and undifferentiated components, as well as normal myometrium, was also carried out in one case. According to The Cancer Genome Atlas classification, we distributed 95% of the undifferentiated carcinomas in this series as follows: (a) hypermutated tumors with loss of any mismatch repair protein expression and microsatellite instability (eight cases, 45%); (b) ultramutated carcinomas carrying mutations in the exonuclease domain of POLE (two cases, 11%); (c) high copy number alterations (copy-number high) tumors group exhibiting only TP53 mutations and high number of alterations detected by FISH (two cases, 11%); and (d) low copy number alterations (copy-number low) tumors with molecular alterations typical of endometrioid endometrial carcinomas (five cases, 28%). Two of the latter cases, however, also had TP53 mutations and higher number of alterations detected by FISH and could have progressed to a copy-number high phenotype. Most dedifferentiated carcinomas belonged to the hypermutated group, whereas pure undifferentiated carcinomas shared molecular genetic alterations with copy-number low or copy-number high tumors. These results indicate that undifferentiated and dedifferentiated endometrial carcinomas are molecularly heterogeneous tumors, which may have prognostic value.
未分化和去分化子宫内膜癌是子宫癌中罕见且侵袭性很强的亚型,在分子水平上特征尚不明确。为了研究去分化癌是否携带与纯未分化癌相似的分子遗传改变,并深入了解这些肿瘤的发病机制,我们选取了一组18例未分化子宫内膜癌,其中8例伴有高分化子宫内膜样癌成分(去分化子宫内膜样癌),通过免疫组化、大规模平行测序和桑格测序对其进行研究。还对其中1例病例的子宫内膜样和未分化成分以及正常子宫肌层进行了全外显子测序。根据癌症基因组图谱分类,我们将本系列中95%的未分化癌分类如下:(a) 任何错配修复蛋白表达缺失且微卫星不稳定的高突变肿瘤(8例,45%);(b) 在POLE外切酶结构域携带突变的超突变癌(2例,11%);(c) 仅表现TP53突变且通过荧光原位杂交检测到大量改变的高拷贝数改变(拷贝数高)肿瘤组(2例,11%);以及(d) 具有子宫内膜样子宫内膜癌典型分子改变的低拷贝数改变(拷贝数低)肿瘤(5例,28%)。然而,后两组中的2例也有TP53突变,并且通过荧光原位杂交检测到更多改变,可能已进展为拷贝数高的表型。大多数去分化癌属于高突变组,而纯未分化癌与拷贝数低或拷贝数高的肿瘤具有共同的分子遗传改变。这些结果表明,未分化和去分化子宫内膜癌是分子异质性肿瘤,可能具有预后价值。